TY - JOUR
T1 - Microbubble Agents: New Directions
AU - Stride, Eleanor
AU - Segers, Tim
AU - Lajoinie, Guillaume
AU - Cherkaoui, Samir
AU - Bettinger, Thierry
AU - Versluis, Michel
AU - Borden, Mark
PY - 2020/6
Y1 - 2020/6
N2 - Microbubble ultrasound contrast agents have now been in use for several decades and their safety and efficacy in a wide range of diagnostic applications have been well established. Recent progress in imaging technology is facilitating exciting developments in techniques such as molecular, 3-D and super resolution imaging and new agents are now being developed to meet their specific requirements. In parallel, there have been significant advances in the therapeutic applications of microbubbles, with recent clinical trials demonstrating drug delivery across the blood–brain barrier and into solid tumours. New agents are similarly being tailored toward these applications, including nanoscale microbubble precursors offering superior circulation times and tissue penetration. The development of novel agents does, however, present several challenges, particularly regarding the regulatory framework. This article reviews the developments in agents for diagnostic, therapeutic and “theranostic” applications; novel manufacturing techniques; and the opportunities and challenges for their commercial and clinical translation.
AB - Microbubble ultrasound contrast agents have now been in use for several decades and their safety and efficacy in a wide range of diagnostic applications have been well established. Recent progress in imaging technology is facilitating exciting developments in techniques such as molecular, 3-D and super resolution imaging and new agents are now being developed to meet their specific requirements. In parallel, there have been significant advances in the therapeutic applications of microbubbles, with recent clinical trials demonstrating drug delivery across the blood–brain barrier and into solid tumours. New agents are similarly being tailored toward these applications, including nanoscale microbubble precursors offering superior circulation times and tissue penetration. The development of novel agents does, however, present several challenges, particularly regarding the regulatory framework. This article reviews the developments in agents for diagnostic, therapeutic and “theranostic” applications; novel manufacturing techniques; and the opportunities and challenges for their commercial and clinical translation.
KW - Cavitation nuclei
KW - Microbubbles
KW - Nanodroplets
KW - Theranostic
KW - Ultrasound contrast agents
UR - http://www.scopus.com/inward/record.url?scp=85081238439&partnerID=8YFLogxK
U2 - 10.1016/j.ultrasmedbio.2020.01.027
DO - 10.1016/j.ultrasmedbio.2020.01.027
M3 - Review article
AN - SCOPUS:85081238439
VL - 46
SP - 1326
EP - 1343
JO - Ultrasound in medicine and biology
JF - Ultrasound in medicine and biology
SN - 0301-5629
IS - 6
ER -